Ignite Creation Date:
2024-05-06 @ 12:31 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03786107
Status:
TERMINATED
Last Update Posted:
2021-05-19
First Post:
2018-12-20
Brief Title:
HER-Seq A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
Sponsor:
Puma Biotechnology Inc
Organization:
Puma Biotechnology Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Metastatic Cervical Cancer |
| Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer |